Literature DB >> 1532346

Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.

C Aschele1, A Sobrero, M A Faderan, J R Bertino.   

Abstract

Mechanisms of resistance to 5-fluorouracil (FUra) were compared between a cell line resistant to a short-term exposure (4 h) to this agent (HCT-8/FU4hR) and a cell line resistant to a prolonged exposure (7 days) to the fluoropyrimidine (HCT-8/FU7dR). The two cell lines were obtained by repeatedly exposing 2 x 10(5) cells to a constant concentration of FUra (1000 microM for 4 h or 15 microM for 7 days), able to produce 3-4 logs of cell kill. HCT-8/FU4hR cells were still sensitive to FUra given as a 7-day exposure, suggesting different mechanisms of resistance. In addition, HCT-8/FU7dR cells were cross-resistant to fluorodeoxyuridine and, to a lesser degree, methotrexate; while HCT-8/FU4dR cells were not. Both HCT-8/FU4hR and HCT-8/FU7dR cells were similar to parental HCT-8 cells with regard to uptake of FUra as well as the pattern of FUra-metabolizing and FUra target enzymes. Although neither in situ thymidylate synthase (TS) activity nor the degree of its inhibition by FUra showed any evidence of alteration in HCT-8/FU7dR cells, a rapid recovery of TS activity after drug removal was evident in this cell line. The addition of as much as 100 microM leucovorin did not completely inhibit the recovery of thymidylate synthesis after FUra exposure. No differences were detected in the kinetic properties (Km for 2'-deoxyuridylate and 5,10-methylenetetrahydrofolate, concentration producing 50% inhibition for fluorodeoxyuridylate) or TS from HCT-8/FU7dR cells as compared to parental HCT-8 TS. Baseline levels of 5,10 methylenetetrahydrofolate were decreased in HCT-8/FU7dR cells, and analysis of the chain length distribution of the polyglutamylated form of the folate cofactor showed that in this cell line the defect in 5,10-methylenetetrahydrofolate levels is accompanied by, and possibly due to, a defect in the polyglutamylation of this cofactor. In contrast, HCT-8/FU4hR cells were similar to the parental cell line with regard to both the degree of in situ TS inhibition by FUra and duration of inhibition after FUra removal. Labeling studies with [3H-6]FUra (4 h exposure, 100 microM) showed that the incorporation of the fluoropyrimidine into RNA is significantly decreased in HCT-8/FU4hR cells as compared to parental HCT-8 cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532346

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; G R Hudes; F Greene; F P LaCreta; J Brennan; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

3.  Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.

Authors:  H Petrowsky; G D Roberts; D A Kooby; B M Burt; J J Bennett; K A Delman; S F Stanziale; T M Delohery; W P Tong; H J Federoff; Y Fong
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 4.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 5.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

6.  Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model.

Authors:  D Burke; P Carnochan; C Glover; T G Allen-Mersh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 7.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

Review 8.  Chemotherapeutic drug resistance in the management of head and neck cancer.

Authors:  H Bier
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 9.  First-line treatment strategies to improve survival in patients with advanced colorectal cancer.

Authors:  Sharlene Gill; Richard M Goldberg
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer.

Authors:  Yasuhiro Inoue; Koji Tanaka; Junichiro Hiro; Yuji Toiyama; Chikao Miki; Masato Kusunoki
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.